Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.64 |
| ▸ | PPARA | Q07869 | 6/20 | 0.64 |
| ▸ | ESRRA | P11474 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7831811 | 0.91 | PPARG (0.61) | PPARGFFAR1PPARAESRRAHRH3 | |
| SCHEMBL7835362 | 0.91 | PPARG (0.61) | PPARGFFAR1PPARAESRRAHRH3 | |
| SCHEMBL7836370 | 0.89 | FFAR1 (0.65) | PPARGFFAR1PPARAESRRA | |
| SCHEMBL6900078 | 0.86 | PPARG (0.69) | PPARGFFAR1PPARAESRRAHRH3 | |
| SCHEMBL1130955 | 0.86 | PPARG (0.79) | PPARGFFAR1PPARAESRRA | |
| SCHEMBL7837758 | 0.86 | PPARG (0.65) | PPARGFFAR1PPARAESRRA | |
| SCHEMBL7835177 | 0.86 | PPARG (0.67) | PPARGFFAR1PPARAESRRAHRH3 | |
| SCHEMBL6900101 | 0.86 | PPARG (0.68) | PPARGFFAR1PPARAESRRAHRH3 | |
| SCHEMBL1130791 | 0.85 | PPARG (0.73) | PPARGFFAR1PPARAESRRAHRH3 | |
| SCHEMBL7838277 | 0.85 | PPARG (0.67) | PPARGFFAR1PPARAESRRAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0919232-B1 | Composition for use in the treatment and prevention of hyperuricemia | SANKYO CO (JP) | 2004-10-06 | — | — | EP | claimed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | claimed |
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | claimed |
| US-6150371-A | WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 2000-11-21 | — | — | US | claimed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | claimed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | claimed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | claimed |
| JP-9165371-A | — | — | None | — | — | JP | disclosed |
| JP-7330728-A | — | — | None | — | — | JP | disclosed |
| EP-0919232-B1 | Composition for use in the treatment and prevention of hyperuricemia | SANKYO CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | disclosed |
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6150371-A | WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| JP-H09165371-A | MEDICINE CONTAINING HETEROCYCLIC COMPOUND | SANKYO CO LTD | 1997-06-24 | — | — | JP | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| JP-H07330728-A | HETEROCYCLIC COMPOUND | SANKYO CO LTD | 1995-12-19 | — | — | JP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |